KRAS and familial pancreatic carcinoma: The KRASG12R mutation, which accounts for approximately 15% of the KRAS mutations in pancreatic cancer but less than 1% of the KRAS mutations in lung cancer, was reported to be associated with different downstream signaling pathways relative to other KRAS mutations27.